Sign In
Buy PCRX
$22.32
+0.0700 (+0.315%)
At Close: Jun 03, 2026
Community Health (CYH) Unit Declares Pricing of Senior Notes
06:52pm, Friday, 21'st Jan 2022 Zacks Investment Research
Community Health's (CYH) wholly-owned arm exhibits monetary discretion by pricing senior notes to procure funds.
The Zacks Analyst Blog Highlights: Pacira BioSciences, D.R. Horton ArcBest, Axis Capital Holdings and CF Industries
12:04pm, Thursday, 20'th Jan 2022 Zacks Investment Research
Pacira BioSciences, D.R. Horton ArcBest, Axis Capital Holdings and CF Industries are highlighted in this Analyst Blog Article.
5 Reasons to Bet On These 5 Buy Ranked Stocks
02:22pm, Wednesday, 19'th Jan 2022 Zacks Investment Research
PCRX, DHI, ARCB, AXS and CF balance value and growth and are therefore worth picking up.
5 Reasons to Bet On These 5 Buy Ranked Stocks
10:45am, Wednesday, 19'th Jan 2022
PCRX, DHI, ARCB, AXS and CF balance value and growth and are therefore worth picking up.
Here's Why Seasoned Investors are Retaining Mednax (MD)
04:55pm, Wednesday, 12'th Jan 2022 Zacks Investment Research
Banking on its strategic measures and a streamlined business, Mednax (MD) holds potential to reap benefits for investors.
BioCryst (BCRX) Stock Up on Q4 Orladeyo Preliminary Sales
04:13pm, Tuesday, 11'th Jan 2022 Zacks Investment Research
BioCryst's (BCRX) sole marketable drug, Orladeyo reports preliminary sales for the fourth quarter. The company also provides its revenue guidance for 2022.
Why Seasoned Investors are Retaining Community Health (CYH)
03:42pm, Tuesday, 11'th Jan 2022 Zacks Investment Research
Community Health Systems (CYH) is focused on making strategic acquisitions to boost its business through inorganic growth.
Here's Why You Should Retain Centene (CNC) in Your Portfolio
05:20pm, Friday, 07'th Jan 2022 Zacks Investment Research
Centene (CNC) is well poised for growth on the back of improving revenues, continuous expansion plans for the MA business and sufficient cash-generating abilities.
Amgen (AMGN) Inks Multi-Target Deal to Make Protein Therapeutics
03:24pm, Friday, 07'th Jan 2022 Zacks Investment Research
Amgen (AMGN) signs a collaboration agreement with Generate Biomedicines to develop protein therapeutics across several therapeutic areas and multiple modalities.
Pacira (PCRX) is an Incredible Growth Stock: 3 Reasons Why
05:45pm, Tuesday, 04'th Jan 2022 Zacks Investment Research
Pacira (PCRX) could produce exceptional returns because of its solid growth attributes.
Pacira (PCRX) is an Incredible Growth Stock: 3 Reasons Why
01:50pm, Tuesday, 04'th Jan 2022
Pacira (PCRX) could produce exceptional returns because of its solid growth attributes.
Pacira BioSciences: Higher Prices On The Horizon
11:39am, Monday, 20'th Dec 2021
The company reports an EPS beat of $0.72 in the third quarter. We look into how management has been employing its capital.
Pacira BioSciences Announces Closing of $375 Million Five-Year Term Loan B
01:00pm, Thursday, 09'th Dec 2021 GlobeNewswire Inc.
-- Provides additional operational and financial flexibility -- -- Underscores strength of forecasted earnings and operating cash flow --
Pacira (PCRX) Down 4.5% Since Last Earnings Report: Can It Rebound?
04:31pm, Friday, 03'rd Dec 2021 Zacks Investment Research
Pacira (PCRX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Pacira BioSciences to Present at the Piper Sandler 33rd Annual Virtual Healthcare Conference
01:00pm, Tuesday, 23'rd Nov 2021 GlobeNewswire Inc.
TAMPA, Fla., Nov. 23, 2021 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced that it will participate in an analyst-led fireside chat at the Piper Sandler 33rd Annual Virtu
